Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Zubiaur

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Pharmacogenomics|November 4, 2022
CYP2C18: the orphan in the CYP2C familyPablo Zubiaur, Andrea Gaedigk
Pharmacogenomics|November 22, 2022
Use of pharmacogenetics for benzodiazepine prescription: state of the art and expectationsPablo Zubiaur, Francisco Abad-Santos
Pharmaceutics|January 21, 2023
Association Studies in Clinical PharmacogeneticsPablo Zubiaur, Francisco Abad-Santos
Pharmacogenetics and Genomics|April 26, 2023
'Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation' by Ali et al. - reassess the evidence, shall we?Miriam Saiz-Rodríguez, Pablo Zubiaur, Francisco Abad-Santos
Advances in Therapy|December 26, 2019
Author's Response to: 'Letter to the Editor in Response to: "Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally"'Pablo Zubiaur, Miriam Saiz-Rodríguez, Francisco Abad-Santos
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 13, 2022
"Pharmacogenetics of siponimod: A systematic review" by Díaz-Villamarín et al. - Information is powerPablo Zubiaur, Miriam Saiz-Rodríguez, Francisco Abad-Santos
Clinical Pharmacology and Therapeutics|November 16, 2023
Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?"Pablo Zubiaur, J Steven Leeder, Francisco Abad-Santos, et al.
Clinical Pharmacokinetics|June 14, 2021
Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic ApproachLisa Alina Kneller, Pablo Zubiaur, Dora Koller, et al.
Talanta|March 17, 2019
Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparationDora Koller, Pablo Zubiaur, Miriam Saiz-Rodríguez, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic ReviewHouwaida Abbes, Paula Soria-Chacartegui, Asma Omezzine, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Pharmacogenomics|November 4, 2022
CYP2C18: the orphan in the CYP2C familyPablo Zubiaur, Andrea Gaedigk
Pharmacogenomics|November 22, 2022
Use of pharmacogenetics for benzodiazepine prescription: state of the art and expectationsPablo Zubiaur, Francisco Abad-Santos
Pharmaceutics|January 21, 2023
Association Studies in Clinical PharmacogeneticsPablo Zubiaur, Francisco Abad-Santos
Pharmacogenetics and Genomics|April 26, 2023
'Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation' by Ali et al. - reassess the evidence, shall we?Miriam Saiz-Rodríguez, Pablo Zubiaur, Francisco Abad-Santos
Advances in Therapy|December 26, 2019
Author's Response to: 'Letter to the Editor in Response to: "Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally"'Pablo Zubiaur, Miriam Saiz-Rodríguez, Francisco Abad-Santos
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 13, 2022
"Pharmacogenetics of siponimod: A systematic review" by Díaz-Villamarín et al. - Information is powerPablo Zubiaur, Miriam Saiz-Rodríguez, Francisco Abad-Santos
Clinical Pharmacology and Therapeutics|November 16, 2023
Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?"Pablo Zubiaur, J Steven Leeder, Francisco Abad-Santos, et al.
Clinical Pharmacokinetics|June 14, 2021
Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic ApproachLisa Alina Kneller, Pablo Zubiaur, Dora Koller, et al.
Talanta|March 17, 2019
Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparationDora Koller, Pablo Zubiaur, Miriam Saiz-Rodríguez, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic ReviewHouwaida Abbes, Paula Soria-Chacartegui, Asma Omezzine, et al.
Pageof 9